These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-001605-10 A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate not-yet-due
Ongoing 2005-000833-39 RANDOMIZED STUDY WITH POSTOPERATIVE RADIOTHERAPY AND CONCURRENT LOW DOSE CISPLATIN VS RADIOTHERAPY AND CONCURRENT CISPLATIN + FLUOROURACIL IN OPERATED HIGH RISK SQUAMOUS CELL CARCINOMA OF THE ... not-yet-due
Ongoing 2005-000838-21 RANDOMIZED STUDY OF RADIOTHERAPY WITH CONCOMITANT BOOST (RTcb) AND CONCURRENT LOW DOSE CISPLATIN VS RTcb AND CISPLATIN + FLUOROURACIL IN ADVANCED HNSCC not-yet-due
Ongoing 2005-003369-17 A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell Lymphoma not-yet-due
Ongoing 2005-003676-38 CAPECITABINE TIME TABLE AND RADIOTHERAPY AS ADJUVANT THERAPY IN RECTAL CANCER not-yet-due
Completed, but no date Terminated 2005-003701-91 ONCE WEEKLY DOSING OF DARBEPOETIN ALPHA AS PROPHYLACTIC TREATMENT FOR ANEMIA IN ELDERLY CANCER PATIENTS bad-data
Ongoing 2006-003151-21 Study to compare the tolerability of slow release oxycodone versus slow release morphine in the treatment of severe cancer pain. The study is geared towards a clinical practice improvement. not-yet-due
Completed, but no date, and reported results Terminated 2006-004234-33 Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL bad-data
Ongoing 2006-005009-69 TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY not-yet-due
Completed, but no date, and reported results 2007-003657-87 Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas bad-data
Completed, but no date, and reported results 2008-000080-42 A Phase II study of Chetoconazolo in patients with Metastatic Hormone-Refractory Prostate Cancer. Pilot study bad-data
Ongoing 2008-001062-93 Perioperative treatment with COI-E (capecitabine, oxaliplatin, irinotecan and cetuximab) of liver metastasis of colorectal carcinoma potentially resectable although at high risk of recurrences not-yet-due
Ongoing 2008-002202-18 CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS not-yet-due
Ongoing 2008-002454-37 intrarterial chemotherapy with liposomial doxorubicin for recurrent glioblastoma affected patients. Phase II study. not-yet-due
Ongoing 2008-005176-28 A PROSPECTIVE PHASE II MULTICENTRIC STUDY OF WEEKLY TOPOTECAN AND CISPLATIN (TOPOCIS) AS NEOADJUVANT TREATMENT IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CERVICAL CANCER not-yet-due
Ongoing 2008-006527-30 Preventing Breast cancer through Assumption of Metformin, Diet and Physical Activity not-yet-due
Ongoing 2009-009418-42 Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy on ... not-yet-due
Ongoing 2009-014301-14 Farmacologic prevention with Varenicline in heavy smokers undergoing early detection lung cancer screening not-yet-due
Ongoing 2009-014456-29 PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA not-yet-due
Completed, but no date 2009-015909-39 Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly bad-data
Ongoing 2009-017093-20 Phase 2 study with the multi-targeted tyrosine-kinase inhibitor Pazopanib (GW786034) for patients with relapsed or refractory urothelial cancer not-yet-due
Ongoing 2009-017798-39 An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) not-yet-due
Reported results 2010-018869-29 PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT) 2013-10-04 due-trials
Ongoing 2010-020305-32 A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as fi... not-yet-due
Ongoing 2010-020375-24 Sorafenib in recurrent and/or metastatic salivary gland carcinomas not-yet-due
Completed, but no date, and reported results 2010-021557-40 A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE ... bad-data
Ongoing 2010-021658-21 Phase II study of preoperative TPF chemotherapy in locally advanced resectable oral cavity squamous cell cancer in order to improve the rate of pathological complete response not-yet-due
Ongoing 2010-021755-34 Phase II study on imatinib in combination with RAD001 in advanced chordoma not-yet-due
Ongoing 2010-021898-36 Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment. not-yet-due
Ongoing 2010-022653-41 Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder. not-yet-due
Listed as ongoing, but also has a completion date and reported results 2010-023135-42 INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA... 2019-05-03 bad-data
Ongoing 2011-002564-24 Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer Cetuximab e Cisplatino con o senza Paclitaxel nel tumore testa-collo ricorrente o metastatico not-yet-due
Ongoing 2011-002632-99 SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma SUTNET Trial: Studio Clinico-Biologico Di Fase II Co... not-yet-due
Ongoing 2011-005248-81 Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry Carcinoma tiroideo differenziato: radioterapia metabolica con ... not-yet-due
Ongoing 2011-005327-41 Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormono-... not-yet-due
Ongoing 2011-005983-12 Phase II study of the fully human monoclonal antibody against transforming growth factor-beta (TGF-beta) receptor ALK1 (PF-03446962) in relapsed or refractory urothelial cancer (UC) failing first-line... not-yet-due
Ongoing 2011-006205-95 Toremifene in desmoid tumor: prospective clinical trial and identification of potential molecular targets Toremifene nel tumore desmoide: studio clinico prospettico e identificazione di potenziali ... not-yet-due
Ongoing 2011-006234-16 Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refracto... not-yet-due
Ongoing 2012-000382-20 Peritoneal Mesothelioma: Optimize Outcomes by the Integration of new Prognostic Factors and Potential Therapeutic Targets in a Individualized Treatment based on Molecular Characterization and Chemosen... not-yet-due
Completed, but no date 2012-000708-14 A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of Sorafenib in patients with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases. Studio r... bad-data
Ongoing 2012-001103-21 MANTAINANCE METRONOMIC PER OS NAVELBINE IN ADVANCED NSCLC PATIENTS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: A MULTICENTER RANDOMIZED BEST SUPPORTIVE CARE CONTROLLED PHASE II STUDY: MA.NI.LA. TRIAL.... not-yet-due
Reported results Terminated 2012-002059-40 Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients Potenziamento degli effetti clinici e immun... 2013-06-20 due-trials
Completed, but no date 2012-002460-27 Preoperative skin preparation to lower surgical site infection in breast cancer surgery: Povidone – iodine 10% aqueous solution versus 2%chlorhexidine in 70% isopropyl alcohol (ChloraPrep, Cardinal H... bad-data
Completed, but no date, and reported results Terminated 2012-003590-25 Phase II study of the Pan-HER inhibitor Dacomitinib (PF-00299804) for patients with locally advanced or metastatic squamous cell carcinoma of the penis Phase II study of the Pan-HER inhibitor Dacom... bad-data
Completed, but no date 2012-004910-33 Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT). Studio di fase II con ™inibitore tirosin-kinasico Pazopanib in pazienti affetti ... bad-data
Completed, but no date, and reported results Terminated 2012-004956-12 A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and corre... bad-data
Exempt, with results 2012-005157-23 A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL) Studio di Fase I/II di Danusertib in Combinazione con Romidepsina in... not-yet-due
Ongoing 2012-005427-32 Randomized controlled trial of metformin and dietary restriction to prevent age-related morbid events in people with metabolic syndrome Sperimentazione controllata randomizzata di restrizione calo... not-yet-due
Ongoing 2013-000075-33 Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in op... not-yet-due
Ongoing 2013-000580-93 Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable ... not-yet-due
Ongoing 2013-001362-42 Perioperative treatment with COI-B (Capecitabine, Oxaliplatin, Irinotecan and Bevacizumab) of high risk or borderline resectable colorectal liver metastases Trattamento perioperatorio con COI-B (Ca... not-yet-due
Ongoing 2013-003319-23 SUBLINGUAL FENTANYL VERSUS SUBCUTANEOUS MORPHINE FOR THE MANAGEMENT OF SEVERE CANCER PAIN EPISODES IN PATIENTS ON OPIOID TREATMENT: A DOUBLE-BLIND RANDOMIZED NON–INFERIORITY TRIAL. fentanyl subl... not-yet-due
Ongoing 2013-005282-39 Effects of high Intra-abdominal pressure on tissue diffusion and pharmacokinectics of cisplatin during HIPEC Gli effetti dell’alta pressione intra-addominale sulla diffusione tissutale e sulla farm... not-yet-due
Completed, but no date 2013-005309-30 open label, randomized, pilot study on the activity of olanzapine with or without delayed dexamenthasone versus dexamenthasone alone for the prevention of delayed nausea and vomiting in patients with ... bad-data
Ongoing 2013-005596-40 Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor Studio di fase 2 su Axitinib nel tumore solitario fibroso avanzato not-yet-due
Ongoing 2014-000043-32 A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract not-yet-due
Completed, but no date, and reported results 2014-000334-30 Immunomodulatory effect of esomeprazole antitumoral and high-dose under neoadjuvant and adjuvant in patients with melanoma in stage III. Randomized pilot study treatment vs control EFFETTO IMMUNOMO... bad-data
Completed, but no date 2014-000557-36 A Phase 2 study of the Aurora kinase A inhibitor Alisertib (MLN8237) in patients with relapsed or refractory transitional-cell carcinoma of the bladder and urothelial tract Studio di fase 2 con l’i... bad-data
Not reported Terminated 2014-000777-38 Activity and safety of second line SOrafenib After Pazopanib in patients with metastatic renal cell carcinoma (SOAP Study) Attività e sicurezza della seconda linea con sorafenib dopo pazopanib nei ... 2017-11-08 due-trials
Completed, but no date Terminated 2014-000857-35 An open label, randomized, phase 2 study of Paclitaxel and Panitumumab compared to Paclitaxel alone in patients with relapsed or refractory urothelial cancer. bad-data
Completed, report not yet due 2014-000888-41 Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocen... 2024-09-27 not-yet-due
Not reported 2014-001274-34 Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers. Studio di fase II con abiraterone acetato nel paziente con tumore ... 2023-05-26 due-trials
Not reported Terminated 2014-001956-52 Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study) Attività e sicurezza d... 2017-11-08 due-trials
Ongoing 2014-002021-35 Decurarization After Thoracic Anesthesia - A prospective multicenter double-blind randomized trial comparing sugammadex vs neostigmine reversal after thoracic anesthesia Decurarization After Thora... not-yet-due
Ongoing 2014-002175-28 Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication to... not-yet-due
Completed, but no date, and reported results 2014-002417-36 An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first... bad-data
Ongoing 2014-003227-21 Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole... not-yet-due
Completed, but no date 2015-000333-71 First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the VALENTIN... bad-data
Ongoing 2015-000693-35 Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract Studio di fase II con Lenvatinib in pazienti affe... not-yet-due
Ongoing 2015-000944-41 A PILOT STUDY TO TEST THE FEASIBILITY OF A TWO-ARM, DOUBLE BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED TRIAL FOR THE COMPARISON OF THE DURATION OF THE ANALGESIC EFFICACY OF A SINGLE MATRIX TRANSDERMA... not-yet-due
Listed as ongoing, but also has a completion date 2015-002055-10 PURE-01 An open label, single-arm, phase 2 study of neoadjuvant pembrolizumab (MK-3475) before cystectomy for patients with muscle-invasive urothelial bladder cancer. PURE-01: Studio di Fase 2, in ... 2023-03-15 bad-data
Other 2015-002185-23 Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concomita... not-yet-due
Completed, but no date 2015-002240-14 Targeted Therapy with or without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery Targeted Therapy with or without Nephrectomy in Metastatic Renal Cell Carcino... bad-data
Completed, report not yet due 2015-002629-21 Phase II study on Regorafenib in advanced Solitary Fibrous Tumor Studio di fase 2 su Regorafenib nel tumore fibroso solitario avanzato 2024-10-31 not-yet-due
Not reported 2015-004472-30 Randomized phase III trial on Trabectedin (ET-743) vs clinician's choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients ... 2022-02-24 due-trials
Completed, report not yet due 2015-004596-72 A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration resistant prostate cancer (mCRPC) patients with visceral disease Studio di fase II per valuta... 2023-12-28 not-yet-due
Other 2015-004626-34 Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prosp... not-yet-due
Completed, but no date Terminated 2015-005110-30 A multicenter randomized trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (IP-B... bad-data
Completed, but no date, and reported results Terminated 2016-001688-35 An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors ... bad-data
Ongoing 2016-001783-12 Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: th... not-yet-due
Other 2016-003036-20 A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program Studio randomizzato di prevenzione primaria multifattoriale in so... not-yet-due
Completed, report not yet due 2016-003199-27 PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES Studio di fase 2 con Sunitinib in pazienti affetti da timoma B3 e carcinoma timico, reci... 2024-11-28 not-yet-due
Ongoing 2016-003294-18 Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel In Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients. ... not-yet-due
Not reported 2017-000579-10 An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study Stu... 2022-10-21 due-trials
Other 2017-000580-32 Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-... not-yet-due
Completed, but no date, and reported results Terminated 2017-001963-19 Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) Cabozantinib in pazienti affetti da neoplasia spinoce... bad-data
Completed, report not yet due 2017-002841-31 Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors) Studio di Fase I... 2024-10-02 not-yet-due
Completed, report not yet due 2017-003103-22 Advanced or Metastatic Collecting ducts renal cell carcinoma Cabozantinib nel carcinoma renale dei dotti collettori di Bellini. 2024-07-24 not-yet-due
Completed, but no date Terminated 2017-003706-40 PAZOBONE: First line treatment with Pazopanib in untreated metastatic renal cell carcinoma patients with bone involvement PAZOBONE trial: Terapia di I linea con Pazopanib in pazienti affetti da car... bad-data
Ongoing 2017-003765-10 Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance Immunoterapia seguita da inibitore delle EGFR ... not-yet-due
Completed, report not yet due 2017-004099-71 Randomized Phase II study on Decitabine plus Carboplatin versus physician’s choice chemotherapy in recurrent, platinum-resistant ovarian cancer Studio randomizzato di Fase II su Decitabina più Car... 2024-03-13 not-yet-due
Completed, but no date Terminated 2017-004494-13 IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME. bad-data
Other 2018-000582-36 A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1) Studio di fase 2 in aperto ... not-yet-due
Completed, report not yet due 2018-000655-40 ADJUVANT CAPECITABINE IN HIGH RISK PSEUDOMYXOMA PERITONEI PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) CAPECITABINA ADIUVANTE NEI PAZIENTI ... 2024-10-25 not-yet-due
Completed, report not yet due 2018-000788-95 Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adenocarcinoma: the FAME trial Combinaz... 2024-09-16 not-yet-due
Not reported 2018-004299-37 NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC): the MAYA study. Trattamento di combinazione con NIVOLUMA... 2023-07-10 due-trials
Completed, report not yet due 2019-000105-73 Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study Studio OPTIMAL: Studio di fase II d... 2024-01-31 not-yet-due
Other 2019-003093-13 Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trial Dieta Mima D... not-yet-due
Ongoing 2019-004506-10 A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial ... not-yet-due
Other 2020-000604-11 Phase II study of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer. Studio... not-yet-due
Other 2020-002548-21 Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetry Terapia personalizzata per il trattamento del carcinoma tiroideo metastatico:... not-yet-due
Ongoing 2020-005276-35 ARTesunate in combInation with standard-of-care T-DM1 as Second-line Treatment in patients with advanced HER2-positive breast cancer progressIng on trastuzumab-pertuzumab Chemotherapy: the ARTISTIC st... not-yet-due
Other 2020-005437-32 Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant ... not-yet-due
Other 2021-001385-38 RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN... not-yet-due
Other 2021-002325-18 Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC t... not-yet-due
Other 2021-006229-23 Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. Studio pilota di fase II di... not-yet-due